Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — 15th Bioshares Biotech Summit (July 2019)
22 slides from Anatara Lifesciences's conference presentation, Jul 29, 2019
Slide 1: Anatara Investor Presentation
ASX Release Anatara Investor Presentation For personal use only BRISBANE, 29th July 2019: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the 15th Bioshares Biotech Summit, held in Queenstown
Slide 2: Gut health and the microbiome
Bioshares 2019 Gut health and the microbiome For personal use only
Slide 3: No guts, no glory: why microbiome is so hot right now!
2 No guts, no glory: why microbiome is so hot right now! For personal use only 1 1 1 Nutr Rev. 2012 Aug; 70(Suppl 1): S38–S44
Slide 4: Microbiome research is changing medicine
3 Microbiome research is changing medicine For personal use only Nature2 says The road ahead According to Nature, An area of growing $1.7 billion has been interest, microbiome- based research is changing spent on microbiome the way we treat a wide research in the last 10 range of diseases years A hu
Slide 5: Our place in the microbiome treatment landscape
4 Our place in the microbiome treatment landscape For personal use only Identifying a specific bacterial Drugs that specifically target the Fecal microbiota treatment (FMT) strain, or group of strains, that is bacteria that cause disease while delivered alive to the patient’s leaving the rest of the
Slide 6: Microbiome: broad indications and health opps
5 Microbiome: broad indications and health opps For personal use only Source: http://big.assets.huffingtonpost.com/2015_GutBacteriaA.png
Slide 7: Burgeoning market: our first targets
6 Burgeoning market: our first targets For personal use only Source: http://big.assets.huffingtonpost.com/2015_GutBacteriaA.png
Slide 8: IBS is the most commonly diagnosed gastrointestinal condition
7 For personal use only IBS is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care3 3 IBS Global Impact Report 2018 - https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf
Slide 9: IBS in a minute
8 IBS in a minute 11% For personal use only IBS affects around 11% of the global population4 It costs around $21billion Patients have a poor quality of or more annually in direct medical life and use healthcare system costs and absenteeism5 more than other patients IBS is a functional disorder, requ
Slide 10: Profound impact on patients
9 Profound impact on patients For personal use only “Imagine a day where you fell ill from having eaten too much, then imagine that day lasts months at a time.” Australian IBS patient7 7 IBS Global Impact Report 2018 https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf
Slide 11: IBS - one of the most burdensome chronic ailments reported by patients
10 IBS - one of the most burdensome chronic ailments reported by patients8 For personal use only Individuals with IBS restrict their activities an average of 45% of IBS-D* patients agreed with the statement 73 DAYS a year 8 “I’m willing to try anything to help manage my IBS”9 Patients reported they
Slide 12: USA gastrointestinal health market
11 USA gastrointestinal health market For personal use only US $8b USA digestive remedies and GI supplement sales 8/10 US$5b Adults suffer annually OTC** digestive remedies 2018 10 from a digestive issue10 US$3b ↑ 11.9% GI* supplement sales 201811 OTC** digestive remedies over the past 5 years10 * G
Slide 13: Global consumer health market opportunity
12 Global consumer health market opportunity For personal use only US $5.7b Global probiotic supplement sales 12 Probiotic supplements Other GI supplements OTC digestive supplements Align® (P&G) sales Iberogast® (Bayer) sales Buscopan® (Sanofi) sales (U.S.) 2018: (Germany) 2018: (Global) 2018: US$17
Slide 14: Primary underlying factors of IBS and IBD
13 3 primary underlying factors of IBS and IBD For personal use only
Slide 15: How are these addressed?
14 How are these addressed? Dietary modification For personal use only Probiotics – limited evidence for clinical efficacy Anti-inflammatory drugs – severe GaRP side effect profile No direct treatments with long term results *Gastrointestinal ReProgramming (GaRP) dietary supplement
Slide 16: Changing the game for IBS
15 Changing the game for IBS For personal use only GaRP dietary supplement • Regenerative, multi-component dietary supplement • Dual targeted formulation (small intestine and colon) • Positioned as either an adjunct to existing therapies, or a sole therapy for IBS • Designed to address 3 primary und
Slide 17: Assumption or fact?
16 Assumption or fact? For personal use only Anatara’s Approach: evidence-based complementary medicine • Most complementary medicines are listed, not registered medicines • No requirement for own safety or efficacy studies for listed medicines • Anatara’s approach is to develop its own evidence for
Slide 18: Grounded in scientific evidence
17 Grounded in scientific evidence For personal use only Successful Proof of Concept Studies (February 2019) Demonstrated using industry-standard in vitro gut models
Slide 19: Next steps: human trial
18 Next steps: human trial For personal use only • Pre-clinical animal studies are currently underway where GaRP is being evaluated in a model representative of IBD – Data expected Q4 2019 • Pre-trial activities for a human clinical study in IBS patients have commenced, with a view to study initiati
Slide 20: Future opportunities
19 Future opportunities For personal use only Anatara has the potential to leverage and apply the proprietary know-how and IP created through the development of our GaRP dietary supplement into other gastrointestinal diseases that are caused by a disrupted microbiome, inflammation and mucosal damage
Slide 21: Bringing science to supplements
20 Bringing science to supplements For personal use only • Evidence-based breakthrough product for IBS and IBD – Patentable multi-component, dual-targeted formulation – Delivers the components where they can be most effective 14 • Fewer or lower regulatory requirements than pharmaceuticals – Lower d
Slide 22: Contact Anatara Lifesciences Ltd
21 For personal use only Contact Anatara Lifesciences Ltd Steven Lydeamore, CEO +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — 15th Bioshares Biotech Summit (July 2019) on 6ix